Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Portfolio Pulse from Vandana Singh
Esperion Therapeutics and Otsuka Pharmaceutical announced that their partnered cholesterol drug, bempedoic acid, achieved the primary endpoint in a Phase 3 trial in Japan. The trial showed statistically significant positive outcomes for patients with high LDL cholesterol. Otsuka plans to submit a New Drug Application in Japan in late 2024. Additionally, Esperion received a U.S. Patent Term Extension for bempedoic acid, extending its patent through December 2030. Following the news, Esperion's stock rose by 5.51%.
May 20, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics' cholesterol drug, bempedoic acid, achieved the primary endpoint in a Phase 3 trial in Japan, showing statistically significant positive outcomes. Otsuka plans to submit a New Drug Application in Japan in late 2024. Additionally, Esperion received a U.S. Patent Term Extension for bempedoic acid, extending its patent through December 2030. Following the news, Esperion's stock rose by 5.51%.
The successful Phase 3 trial results in Japan and the planned NDA submission are significant milestones for Esperion Therapeutics. Additionally, the U.S. Patent Term Extension provides long-term value. These factors have positively impacted the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100